Biotech Values

[DewDiligence]

PFE’s Abrocitinib bests Dupixent in_head-to-head_AD—no_futher_details_yet:

https://www.businesswire.com/news/home/20210830005111/en

This is the only phase-3 trial of Abrocitinib that used market-leading Dupixent as a comparator.

The FDA review of PFE’s NDA for Abrocitinib in AD in on hold while the FDA completes its safety review of the entire JAK class.